Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 75

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 75
---
 product candidates fail to be issued, our business will be adversely affected. If we or our licensors are unable to obtain and maintain patent protection for our technology and drugs, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and drugs may be adversely affected.

<div align='center'>39</div>

Our success depends largely
on our ability to obtain and maintain patent protection and other forms of IP rights for the composition of matter, method of use and/or
method of manufacture for each of our drug candidates. Failure to obtain, maintain protection, enforce or extend adequate patent and other
IP rights could materially adversely affect our ability to develop and market one or more of our drug candidates. We also rely on trade
secrets and know-how to develop and maintain our proprietary and IP position for each of our drug candidates. Any failure to protect our
trade secrets and know-how with respect to any specific drug and diagnostics technology candidate could adversely affect the market potential
of that potential product.

As of the date of this proxy
statement/prospectus, the Company has, through its licenses, obtained rights to patents and patent applications covering some or all its
drug and diagnostics technology candidates that have been filed in major jurisdictions such as the United States, member states of
the European Patent Organization (the “EPO”) and the PRC (collectively, “Major Patent Jurisdictions”), as well
as in other countries. We have also filed a number of provisional applications to establish earlier filing dates for certain of our other
ongoing research, the specifics of which are currently proprietary and confidential. To the extent we do not seek or obtain patent protection
in a particular jurisdiction, we may not have commercial incentive to seek marketing authorization in such jurisdiction. Nonetheless,
other parties might enter those markets with generic versions or copies of our products and received regulatory approval without having
significantly invested in their own research and development costs compared to the Company’s investment. For more information about
our IP portfolio, please refer to the Intellectual Property section below.

With respect to issued patents
in certain jurisdictions, for example in the U.S. and under the EPO, we may be entitled to obtain a patent term extension to extend
the patent expiration date provided we meet the applicable requirements for obtaining such patent term extensions. We have sought to support
our proprietary position by working with our licensors in filing patent applications in the names of the licensors in the United States
and through the PCT, related